Vericiguat: Standard Therapy for HFrEF
by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) continued to experience substantial morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT). The prognosis after worsening heart failure (HF) events remained poor, with approximately 37% 1-year all-cause mortality/HFH rates and 19% 1-year mortality despite optimized medical and device […]
Vericiguat: Standard Therapy for HFrEF Read Post »